Suraksha Diagnostic Ltd

Q3 FY26Healthcare Services

Suraksha Diagnostic Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q3 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹326

Market cap₹1.6K Cr

P/E44.4

Updated23 Aug 2026

Read4 min read

The short version

Q3 FY’26 revenue grew 30% YoY, driven by volume expansion and genomics product mix. Suraksha Diagnostic Limited expects strong topline momentum with 30% YoY revenue growth in Q3 FY’26 driven by volume expansion and product mix including genomics.

From Suraksha Diagnostic Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Q3 FY’26 revenue grew 30% YoY, driven by volume expansion and genomics product mix.
Number of patients served increased by 23% YoY in Q3 FY’26.
Number of tests performed grew 30.7% YoY in Q3 FY’26.
Genomics segment showing strong growth: INR2.1-2.2 million monthly run rate and expected to scale further.
Target to add 12-15 new centers annually, including six centers planned for Q4 FY’26 (3 big, 1 PPP, 2 small).
Expansion into new geographies like Northeast India, Bihar, and Jharkhand is planned.
Revenue per patient expected to grow with addition of high-value tests, especially genomics.
No general price hikes expected, but incremental pricing on new tests planned.
Long-term scale expected to improve margins as new centers mature.
Target to reach 100 centers by FY’28, indicating strong growth focus.

Profitability & Margins

Suraksha Diagnostic Limited expects strong topline momentum with 30% YoY revenue growth in Q3 FY’26 driven by volume expansion and product mix including genomics.
EBITDA margins may see a temporary compression (around 32% in FY’26) due to pre-operative costs for new centers but are expected to improve by FY’27 Q3 as new centers mature and economies of scale set in.
The company plans to add 12-15 centers annually, targeting 100 centers by FY’28, supporting long-term revenue growth and scale.
Genomics segment, currently nascent, is expected to grow significantly and become a major growth driver by FY’28.
New geography expansion, including Northeast and Bihar, is expected to replicate revenue per patient levels similar to Kolkata.
Long-term EBITDA margins are anticipated to revert to higher levels with efficient mature centers and cost management.
PAT margin remained stable with growth from 9.3% in Q3 FY’26; future improvements expected with scale.

See what Suraksha Diagnostic Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Suraksha Diagnostic Limited plans to open 12 to 15 new centers annually with a consistent capex of around INR 70 crores per year (Page 12).
For FY’27, the company targets adding five large hub centers and 10 small centers with similar capex (~INR 70 crore) as prior years (Page 12).
In Q4 FY’26, six centers are under development: three big centers, one PPP center, and two small centers; 60-70% expected operational in Q4 with possible spillover into next FY (Page 14).
The company is cautious with PPP centers due to low margins and receivable issues, preferring to deploy capital in other center types (Page 8 & 13).
No increase in capex is anticipated for FY’27 beyond 70 crores; focus remains on expansion and scaling existing business (Page 12).

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹981 Cr

Rev 1Mar 1

2CHANDAN₹518 Cr

Rev 1Mar 3

3₹66.5K Cr

Rev 2Mar 1

4₹654 Cr

Rev 2Mar 2

5₹1.3L Cr

Rev 2Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

The transcript from the Suraksha Diagnostic Limited Q3 & 9M FY'26 Earnings Call does not mention any current or planned future fundraising through debt or equity. Specific points on fundraising are absent, indicating: - No explicit discussion on raising capital via debt or equity in the given excerpts. - The company is focusing on expansion primarily through internal accruals and targeted capex (INR 70 crores annually for 12-15 centers). - Strategic growth emphasis is on scaling existing operations and expanding into new geographies like Northeast India, Bihar, and Jharkhand, rather than seeking external fundraising. - No indications of immediate plans for fundraising were provided during the Q&A or management remarks. Hence, based on the available data, Suraksha Diagnostic Limited has not disclosed any current or future fundraising plans through debt or equity.

See what Suraksha Diagnostic Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly mention the current or expected order book or pending orders for Suraksha Diagnostic Limited. However, some relevant points about ongoing projects and expansions include: - Six centers are under development for Q4 FY’26: 3 large centers, 1 PPP center, and 2 small centers. - Expected to operationalize around 60-70% of these centers by Q4 FY’26; 1-2 centers may spill into the next financial year. - Targeting to reach 100 centers by FY’28. - Plan to add 12 to 15 centers annually with a capex of around INR 70 crores. - Expansion into new geographies like Northeast India, Bihar, and Jharkhand is planned for the next financial year. No specific order backlog or pending contractual orders are disclosed in the transcript.

Suraksha Diagnostic Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹81 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Suraksha Diagnostic Ltd's management said in earlier quarters

Others in Healthcare Services this season

Vijaya Diagnostic Centre Ltd (Q3 FY26)
FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnost.'s Q3 FY26 earnings call — and…
Aster DM Quality Care Ltd (Q3 FY26)
Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…
Chandan Healthcare Ltd (Q3 FY26)
The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…
Rainbow Childrens Medicare Ltd (Q3 FY26)
Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare Institute Ltd vs Manipal Health Enterprises Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Suraksha Diagnostic Ltd Q3 FY26 results?

What is Suraksha Diagnostic Ltd share price analysis?

Suraksha Diagnostic Ltd currently shows a neutral. The stock trades at a P/E of 44.4 with a market cap of ₹1,588 Cr. Investors should review the full earnings analysis for detailed insights.

Is Suraksha Diagnostic Ltd planning capital expenditure?

Suraksha Diagnostic Limited plans to open 12 to 15 new centers annually with a consistent capex of around INR 70 crores per year (Page 12).

Keep Suraksha Diagnostic Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.